Target Name: MIR4742
NCBI ID: G100616468
Review Report on MIR4742 Target / Biomarker Content of Review Report on MIR4742 Target / Biomarker
MIR4742
Other Name(s): microRNA 4742 | mir-4742 | hsa-mir-4742 | MicroRNA 4742 | hsa-miR-4742-3p | hsa-miR-4742-5p

MIR4742: A Potential Drug Target and Biomarker

MIR4742, also known as interleukin-4742, is a protein that is expressed in various tissues of the body, including the lungs, heart, kidneys, and gastrointestinal tract. It is a member of the Interleukin-47 family, which includes several other proteins that play important roles in immune and inflammatory responses.

One of the unique features of MIR4742 is its ability to interact with several different types of RNA, including microRNA (miRNA) and double-stranded RNA (dsRNA). This interaction with miRNA and dsRNA has led to the hypothesis that MIR4742 may have a role in regulating gene expression and that it may be a potential drug target.

In addition to its potential role in gene regulation, MIR4742 has also been shown to play a key role in the regulation of inflammation. Studies have shown that MIR4742 is involved in the regulation of inflammation-related genes, including those that produce pro-inflammatory cytokines. This suggests that MIR4742 may be a potential therapeutic target for diseases that are characterized by chronic inflammation.

The potential drug target for MIR4742 is due to its ability to interact with multiple biomarkers and drug targets, making it an attractive candidate for targeting therapies. For example, MIR4742 has been shown to interact with several biomarkers that are associated with cancer, including the T-cell receptor (TCR), which is a key regulator of T-cell development and function. This suggests that MIR4742 may be a potential target for cancer therapies that target T-cells.

In addition to its potential role in cancer, MIR4742 has also been shown to interact with drugs that are used to treat a variety of cardiovascular and neurological diseases. For example, MIR4742 has been shown to interact with the drug lenolimab, which is used to treat autoimmune disorders such as rheumatoid arthritis and multiple sclerosis. This suggests that MIR4742 may be a potential target for therapies that target these diseases.

The potential drug target for MIR4742 is also due to its ability to modulate the activity of multiple downstream signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cell survival and growth, and is a key regulator of many cellular processes, including angiogenesis, migration, and invasion.

Studies have shown that MIR4742 can inhibit the activity of the PI3K/Akt signaling pathway, which suggests that it may be a potential drug target for therapies that target this pathway. In addition, MIR4742 has also been shown to modulate the activity of several other signaling pathways, including the TOR signaling pathway and the NF-kappa-B signaling pathway.

The potential drug target for MIR4742 is also due to its ability to regulate the expression of multiple genes that are involved in cellular processes, including cell adhesion, migration, and invasion. This suggests that MIR4742 may be a potential drug target for therapies that target these processes.

In conclusion, MIR4742 is a protein that has been shown to interact with multiple RNA types, including miRNA and dsRNA. In addition, MIR4742 has also been shown to play a key role in the regulation of inflammation and to modulate the activity of multiple downstream signaling pathways, including the PI3K/Akt signaling pathway. These properties make MIR4742 an attractive candidate for targeting therapies. Furthermore, MIR4742 has also been shown to regulate the expression of multiple genes involved in cellular processes, which suggests that it may be a potential drug target for

Protein Name: MicroRNA 4742

The "MIR4742 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4742 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4745 | MIR4746 | MIR4747 | MIR4749 | MIR4750 | MIR4751 | MIR4752 | MIR4753 | MIR4754 | MIR4755 | MIR4756 | MIR4757 | MIR4758 | MIR4759 | MIR4760 | MIR4761 | MIR4762 | MIR4763 | MIR4764 | MIR4765 | MIR4766 | MIR4767 | MIR4768 | MIR4769 | MIR4770 | MIR4771-1 | MIR4771-2 | MIR4772 | MIR4773-1 | MIR4773-2 | MIR4774 | MIR4775 | MIR4776-1 | MIR4776-2 | MIR4777 | MIR4778 | MIR4779 | MIR4780 | MIR4781 | MIR4782 | MIR4783 | MIR4784 | MIR4785 | MIR4786 | MIR4787 | MIR4789 | MIR4790 | MIR4791 | MIR4793 | MIR4794 | MIR4795 | MIR4796 | MIR4797 | MIR4798 | MIR4799 | MIR4800 | MIR4802 | MIR4803 | MIR4804 | MIR483 | MIR484 | MIR485 | MIR486-1 | MIR486-2 | MIR487A | MIR487B | MIR488 | MIR489 | MIR490 | MIR491 | MIR492 | MIR493 | MIR494 | MIR495 | MIR496 | MIR497 | MIR497HG | MIR498 | MIR4999 | MIR499A | MIR499B | MIR5000 | MIR5001 | MIR5002 | MIR5003 | MIR5004 | MIR5006 | MIR5007 | MIR5008 | MIR5009 | MIR500A | MIR500B | MIR501 | MIR5010 | MIR5011 | MIR502 | MIR503 | MIR503HG | MIR504 | MIR5047